Pharma giant Yapan Bio adds development facility in Genome Valley, KTR opens

HYDERABAD: Piramal Pharma Limited (PPL), which holds a minority stake in Yapan Bio, on Tuesday announced that Yapan Bio expanded its capabilities with a new process development facility at Genome Valley, Hyderabad.

With this expansion, Yapan Bio enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure. The new labs would allow Yapan to optimize the utilization of the GMP facility to support manufacturing of clinical trial material for the clients.

The new facility was inaugurated by Minister for Municipal Administration & Urban Development, Industries & Commerce, and Information Technology of Telangana K T Rama Rao.

At the inaugural, KTR said, "It is heartening to see that Yapan Bio and Piramal Pharma have been continuously expanding from Genome Valley. This is testament to the strength of the biotechnology industry of Telangana. The State of Telangana has been working with the industry to see how to best match our policies and incentives to their constantly evolving needs. We will continue to be a partner for growth and ensure that companies like Yapan Bio continue to grow from the cluster."

Chairperson of Piramal Pharma Ltd Nandini Piramal said, "This new facility, which is part of our 8 million USD expansion plan for Yapan Bio, represents the first major step in the Piramal/Yapan partnership since our initial investment back in December 2021. It's evidence of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients. With this investment, the Yapan team can conduct a larger number of projects than before, resulting in the development and delivery of more novel products for clinical evaluation and ultimately, better, and faster treatments for patients."